Agents Targeting Residual Inflammation
Expert Discussions: Novel Agents Targeting Residual Inflammatory Risk in ASCVD and CKD

Released: August 27, 2024

Expiration: August 26, 2025

Erin Michos
Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Mark J. Sarnak
Mark J. Sarnak, MD, MS

Activity

Progress
1
Course Completed

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.   

 Episode outline:   

  • Colchicine: inhibition of NLRP3 inflammasome assembly/activation
  • Canakinumab (anti–IL-1β monoclonal antibody)
  • Ziltivekimab (anti–IL-6 monoclonal antibody)
  • Other emerging targets/therapies

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below: